Navigation Links
Pitt-led network gets $70 million over 7 years to develop, test HIV prevention products
Date:12/17/2013

PITTSBURGH, Dec. 17, 2013 With funding of $70 million to support its effort into 2021, the Microbicide Trials Network (MTN) will continue to develop and test products that aim to reduce the spread of HIV, the virus that causes AIDS, federal officials announced yesterday. The extensive program, which is based at the University of Pittsburgh and Magee-Womens Research Institute (MWRI), has completed 13 trials since 2006; 11 more are in progress or will begin within the year; and several new studies will be designed and implemented during the next funding period.

The MTN was created in 2006 with funding from the National Institute of Allergy and Infectious Diseases (NIAID), as well as the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Mental Health, all part of the National Institutes of Health. The new funding means the MTN will continue to serve as one of five NIAID HIV/AIDS clinical trials networks for the next seven years. The MTN brings together international investigators and community and industry partners whose work is focused on the development and rigorous evaluation of promising microbicides, which are products applied inside the vagina or rectum that are intended to prevent the sexual transmission of HIV.

"Although progress in the field of HIV prevention and treatment has been nothing short of breathtaking over the last decade, there are two groups who continue to have high rates of new HIV infections young women and men who have sex with men. The MTN is focused on developing products to address their unmet needs.," said co-principal investigator Sharon Hillier, Ph.D., professor and vice chair for faculty affairs, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, and an MWRI member. "To address the HIV epidemic in young women, we currently are conducting a large Phase III trial of a vaginal ring that women use for a month at a time. Moving forward, we are committed to developing products that could prevent both HIV and unwanted pregnancy, which would empower young women to take charge of their own reproductive health."

Another high-priority research area is to address the unmet need for new HIV prevention products for use by men who have sex with men, transgender women, and heterosexual women who have anal sex, said co-principal investigator Ian McGowan, M.D., Ph.D., professor of medicine, Division of Gastroenterology, Hepatology and Nutrition, Pitt School of Medicine, and an MWRI member.

"Ultimately, we want to identify a lubricant-like product that both men and women can use to protect themselves from acquiring HIV during anal sex," he said. "Our entire scientific agenda is focused on conducting the kind of studies that can get safe and effective HIV prevention products approved for widespread use, whether these be vaginal or rectal microbicides. Clearly, we can't end the HIV epidemic with condoms alone."

The MTN is composed of three major components: a leadership and operations center, which is led by Drs. Hillier and McGowan; a laboratory center, based at MWRI and led by Charlene Dezzutti, Ph.D., associate professor of obstetrics, gynecology and reproductive sciences, Pitt School of Medicine; and a statistical data and management center based at the Fred Hutchinson Cancer Research Center in Seattle. The $70 million from NIAID supports the work of the MTN's leadership and operations center and the laboratory center. The network is affiliated with more than 25 clinical research sites in Africa, North America, South America and Asia, which are part of NIAID-funded clinical trials units (CTUs).

NIAID officials also announced today that Pitt has been awarded a seven-year, $8.7 million grant to continue as one of 37 CTUs for HIV/AIDS research. The CTUs are responsible for implementing the scientific agendas of NIAID's networks. John Mellors, M.D., professor of medicine and chief, division of infectious diseases, Pitt School of Medicine, is the principal investigator for the unit, which will oversee MTN studies conducted at Pitt and studies of the AIDS Clinical Trial Group (ACTG), another NIH-funded clinical trials network, at research sites at Pitt and Ohio State University. Dr. Mellors also leads the virology cores of the MTN's and ACTG's laboratory centers and the ACTG's efforts to cure HIV infection.


'/>"/>

Contact: Anita Srikameswaran
SrikamAV@upmc.edu
412-578-9193
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

Related biology news :

1. Singapore joins global translational medicine network as Asia-Pacific hub
2. Neurofeedback tunes key brain networks, improving subjective well-being in PTSD
3. An abnormal resting-state functional brain network indicates progression towards AD
4. Study finds gene network associated with alcohol dependence
5. European young investigators network for Usher syndrome awarded E-Rare collab project
6. Social networks make us smarter
7. UNH, UC Davis launch network to study environmental microbes
8. Network to study environmental microbes
9. 23 researchers join network of EMBO Young Investigators
10. EUREKA grant to fund development of new optogenetic technique for mapping neural networks at UMMS
11. Rice, MD Anderson researchers win NIH grant to study protein networks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. (NASDAQ: ... announces the filing of its 2016 Annual Report on Form 10-K ... Commission. ... 10-K is available in the Investor Relations section of the Company,s ... the SEC,s website at http://www.sec.gov . 2016 Year ...
(Date:4/11/2017)... , Apr. 11, 2017 Research and Markets ... 2017-2021" report to their offering. ... The global eye tracking market to grow at a CAGR ... Global Eye Tracking Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
(Date:4/5/2017)...  The Allen Institute for Cell Science today announces ... portal and dynamic digital window into the human cell. ... application of deep learning to create predictive models of ... a growing suite of powerful tools. The Allen Cell ... publicly available resources created and shared by the Allen ...
Breaking Biology News(10 mins):
(Date:8/16/2017)... ... August 16, 2017 , ... Tunnell Consulting announced today that ... ISPE Annual Meeting and Expo , to be held October 29 through November ... is “Driving innovation to advance patient therapies.” , The ISPE Annual Meeting and Expo ...
(Date:8/16/2017)... Linda, Ca (PRWEB) , ... August 16, 2017 ... ... treatment by changing into a different cell type. Many treatments for specific cancers, ... A prominent example of targeted treatment is androgen deprivation therapy for advanced prostate ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... delivery system, announced it has secured $2M in funding from an impressive group ... Carmen Innovations, and SVG Thrive Fund. With this investment, 3Bar is broadening availability ...
(Date:8/16/2017)... WAKEFIELD, Mass. , Aug. 16, 2017  This year,s edition of ... global leader in life sciences workforce solutions, has made the list for ... Inc. 5000 recognizes the nation,s fastest-growing private companies based on a set ... Fast 50, which includes the fastest-growing companies in the Bay ... Inc. 5000 ...
Breaking Biology Technology: